Ionis Pharmaceuticals (NASDAQ:IONS - Get Free Report) had its price objective lifted by stock analysts at UBS Group from $45.00 to $46.00 in a research report issued to clients and investors on Tuesday, MarketBeat.com reports. The brokerage currently has a "neutral" rating on the stock. UBS Group's price target indicates a potential upside of 6.73% from the stock's current price.
IONS has been the topic of a number of other research reports. HC Wainwright reissued a "buy" rating and issued a $65.00 price target (up previously from $50.00) on shares of Ionis Pharmaceuticals in a research report on Thursday, July 31st. JPMorgan Chase & Co. boosted their target price on shares of Ionis Pharmaceuticals from $45.00 to $48.00 and gave the stock a "neutral" rating in a research report on Thursday, June 12th. Guggenheim dropped their target price on shares of Ionis Pharmaceuticals from $65.00 to $64.00 and set a "buy" rating on the stock in a research report on Thursday, May 1st. Needham & Company LLC dropped their target price on shares of Ionis Pharmaceuticals from $60.00 to $55.00 and set a "buy" rating on the stock in a research report on Wednesday, April 30th. Finally, Barclays raised shares of Ionis Pharmaceuticals from an "equal weight" rating to an "overweight" rating and boosted their target price for the stock from $51.00 to $57.00 in a research report on Tuesday, July 1st. One investment analyst has rated the stock with a sell rating, four have issued a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, Ionis Pharmaceuticals currently has an average rating of "Moderate Buy" and a consensus target price of $58.43.
View Our Latest Report on Ionis Pharmaceuticals
Ionis Pharmaceuticals Trading Up 4.1%
NASDAQ:IONS opened at $43.10 on Tuesday. Ionis Pharmaceuticals has a 12 month low of $23.95 and a 12 month high of $50.43. The firm has a market cap of $6.87 billion, a price-to-earnings ratio of -23.42 and a beta of 0.25. The company has a quick ratio of 2.86, a current ratio of 2.87 and a debt-to-equity ratio of 0.99. The company's 50 day moving average is $40.38 and its 200-day moving average is $34.62.
Ionis Pharmaceuticals (NASDAQ:IONS - Get Free Report) last released its quarterly earnings results on Wednesday, July 30th. The company reported $0.70 EPS for the quarter, beating analysts' consensus estimates of $0.19 by $0.51. Ionis Pharmaceuticals had a negative net margin of 28.25% and a negative return on equity of 45.29%. The company had revenue of $452.00 million for the quarter, compared to analyst estimates of $270.90 million. During the same quarter last year, the firm posted ($0.45) earnings per share. The company's quarterly revenue was up 100.9% compared to the same quarter last year. Equities analysts anticipate that Ionis Pharmaceuticals will post -3.5 EPS for the current year.
Insider Buying and Selling at Ionis Pharmaceuticals
In other Ionis Pharmaceuticals news, EVP Richard S. Geary sold 10,000 shares of the business's stock in a transaction on Tuesday, August 5th. The shares were sold at an average price of $42.86, for a total value of $428,600.00. Following the sale, the executive vice president owned 89,492 shares of the company's stock, valued at $3,835,627.12. The trade was a 10.05% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO Brett P. Monia sold 2,432 shares of the business's stock in a transaction on Wednesday, July 30th. The shares were sold at an average price of $45.00, for a total transaction of $109,440.00. Following the completion of the sale, the chief executive officer directly owned 179,820 shares in the company, valued at $8,091,900. This trade represents a 1.33% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 28,141 shares of company stock worth $1,204,806. Corporate insiders own 2.60% of the company's stock.
Institutional Investors Weigh In On Ionis Pharmaceuticals
Institutional investors and hedge funds have recently made changes to their positions in the company. GAMMA Investing LLC boosted its stake in shares of Ionis Pharmaceuticals by 3,786.5% in the 1st quarter. GAMMA Investing LLC now owns 28,993 shares of the company's stock valued at $961,000 after purchasing an additional 28,247 shares in the last quarter. Fifth Third Bancorp boosted its stake in shares of Ionis Pharmaceuticals by 4.8% in the 1st quarter. Fifth Third Bancorp now owns 9,989 shares of the company's stock valued at $301,000 after purchasing an additional 458 shares in the last quarter. Raymond James Financial Inc. acquired a new stake in shares of Ionis Pharmaceuticals in the 4th quarter valued at $3,692,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in shares of Ionis Pharmaceuticals by 20.8% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 9,450 shares of the company's stock valued at $330,000 after purchasing an additional 1,625 shares in the last quarter. Finally, CWM LLC boosted its stake in shares of Ionis Pharmaceuticals by 18.7% in the 1st quarter. CWM LLC now owns 2,435 shares of the company's stock valued at $73,000 after purchasing an additional 384 shares in the last quarter. Institutional investors and hedge funds own 93.86% of the company's stock.
About Ionis Pharmaceuticals
(
Get Free Report)
Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy.
See Also

Before you consider Ionis Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ionis Pharmaceuticals wasn't on the list.
While Ionis Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.